Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.4K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Improving the Understanding of Late Effects of Testicular Cancer in Adolescent and Young Adult Survivors: TRANSCEND-XR.

Andrology·2026
Same author

Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Immunotherapy and tyrosine kinase inhibitors in chordoma: a real-world data study from a European Reference Network on Rare Adult Solid Cancers member center.

Frontiers in oncology·2026
Same author

Management of peripheral-vein leiomyosarcomas, recurrence patterns and individualised treatment strategy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same journal

Clinical Outcomes and Treatment-Related Complications in Triple-Negative Breast Cancer: A Review of 24 Case Reports from 2020 to 2025.

Therapeutics and clinical risk management·2026
Same journal

Differential Effects of Telehealth on Psychological Outcomes in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Therapeutics and clinical risk management·2026
Same journal

Transnasal Humidified Rapid-Insufflation Ventilatory Exchange versus Oropharyngeal Airway-Assisted Face-Mask Ventilation for Gastric Insufflation During Induction of General Anesthesia in Patients at High Risk for Obstructive Sleep Apnea.

Therapeutics and clinical risk management·2026
Same journal

Blood-Based Inflammatory and Metabolic Biomarkers for Assessing Symptom Burden and Quality of Life in Older Adults with Cancer: A Narrative Review.

Therapeutics and clinical risk management·2026
Same journal

The Future of Interventional Keratoconus Management: Perspectives on Integrating Epithelium-on Oxygen-Enriched Cross-Linking into Comprehensive Care Pathways.

Therapeutics and clinical risk management·2026
Same journal

Transcranial Magnetic Stimulation Combined with Speech-Language Therapy for Post-Stroke Aphasia Recovery: A Systematic Review and Network Meta-Analysis.

Therapeutics and clinical risk management·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.4K

Trabectedin for advanced soft tissue sarcomas: optimizing use.

Alison Reid1, Juan Martin-Liberal1, Charlotte Benson1

  • 1Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Therapeutics and Clinical Risk Management
|December 26, 2014
PubMed
Summary
This summary is machine-generated.

Novel agent trabectedin shows promise for advanced soft tissue sarcoma. Optimizing its use requires understanding mechanisms, administration, and response assessment for better patient outcomes.

Keywords:
ET-743myxoid lipoarcomasoptimal administrationsoft tissue sarcomastrabectedin

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K

Related Experiment Videos

Last Updated: Apr 19, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.4K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Soft tissue sarcoma (STS) is a rare cancer with poor prognosis in advanced stages.
  • Current treatments have limitations, necessitating novel therapeutic agents.
  • Trabectedin is an approved agent for advanced STS, but its optimal use requires further investigation.

Purpose of the Study:

  • To review factors influencing the optimization of trabectedin use in soft tissue sarcoma.
  • To discuss the mechanism of action and response assessment for trabectedin.
  • To highlight considerations for trial design and clinical application of trabectedin.

Main Methods:

  • Literature review of trabectedin's efficacy and mechanism in soft tissue sarcoma.
  • Analysis of factors affecting trabectedin's antitumor activity.
  • Discussion of challenges in assessing treatment response, particularly radiologically.

Main Results:

  • Trabectedin demonstrates activity in advanced STS, particularly in second-line or alternative first-line settings.
  • Understanding trabectedin's unique mechanism of action is crucial for optimizing its use.
  • Administration schedule, timing, patient selection, and response assessment are key factors.

Conclusions:

  • Optimizing trabectedin administration, timing, and patient selection can enhance its antitumor activity.
  • Accurate response assessment, distinct from traditional cytotoxic agents, is vital.
  • Further research into trabectedin's specific applications and safety profile is warranted for improved STS management.